Longboard Pharmaceuticals Investor Relations Material
Latest events
Q2 2024
Longboard Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Longboard Pharmaceuticals Inc
Access all reports
Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company primarily focused on developing innovative therapies for neurological diseases. Leveraging its expertise in G protein-coupled receptor (GPCR) technology, Longboard Pharmaceuticals aims to create transformative treatments for these conditions. The company's product candidates are designed to be highly selective with the potential to offer significant improvements over existing therapies. Notably, the company was founded as a spin-off from Arena Pharmaceuticals in 2020 to further advance these specialized drug candidates. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
LBPH
Country
🇺🇸 United States